News
Three people share the hoops they've jumped through, financial strain they've endured and risks they've taken on in order to ...
When Lilly reported strong results from SURMOUNT-1 earlier this year, the drugmaker suggested it may be able to file for approval of tirzepatide in obesity before the end of this year.
Eli Lilly has raised its revenue guidance for 2024 by $3 billion, after reporting strong growth for tirzepatide in diabetes and obesity, fuelled by the end of supply constraints for starting doses.
These can include weight loss, loss of appetite, yellowing of the skin, vomiting or nausea, and the symptoms of diabetes ...
Three people share the hoops they've jumped through, financial strain they've endured and risks they've taken on in order to access life-changing weight loss medications.
For adults with obesity or overweight, tirzepatide-linked improvements in cardiometabolic risk factors are associated with ...
A higher proportion of sleep medicine providers vs. patients reported CPAP over tirzepatide as their preferred treatment option for comorbid obesity and obstructive sleep apnea, according to data ...
Both semaglutide and tirzepatide for type 2 diabetes and weight loss are GLP-1 agonists, meaning they mimic the hormone.
How does Innovent Biologics' mazdutide, a groundbreaking dual GLP-1/glucagon receptor drug just approved in China, compared to Wegovy and Zepbound? Read more here.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results